Business
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society
- Oral presentation to describe distinct receptor binding and mechanistic characteristics of VRDN-001, Company’s lead pipeline candidate in its thyroid eye
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"\n- Oral presentation to describe distinct receptor binding and mechanistic characteristics of VRDN-001, Company’s lead pipeline candidate in its thyroid eye disease program -\n\n\n- Poster presentations to feature data from ongoing Phase 1/2 trial of VRDN-001 -\n\n\n WALTHAM, Mass.--(BUSINESS WIRE)--\nViridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that multiple abstracts featuring data on the Company’s lead investigational therapy for the treatment of thyroid eye disease (TED) will be presented at the Annual Meeting of the Endocrine Society (ENDO 2023) to be held June 15-18, 2023, in Chicago, Illinois.\n\n\nAn oral presentation will highlight mechanistic features of VRDN-001, a full antagonist antibody to the insulin-like growth factor-1 receptor (IGF-1R), in development for TED, while poster presentations will include clinical data from Viridian’s ongoing Phase 1/2 trial of VRDN-001 as well as pharmacodynamic responses in healthy volunteers and patients with active TED receiving VRDN-001.\n\n\nOral Presentation\n\n\nTitle: VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor in Development for Thyroid Eye Disease (TED), Binds to a Distinct Epitope from Teprotumumab\nSession: Thyroid Physiology—From the lab to the patient\nInformation: Saturday, June 17, 2023, 3:45 to 4:00 pm CDT, Session #OR26\n\n\nPoster Presentations\n\n\nTitle: Durability of Treatment Response With VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor, in Patients with Thyroid Eye Disease (TED): Phase 1/2 Clinical Study*\nSession: Thyroid Biology & Cancer: Thyroid Autoimmunity\nInformation: Friday, June 16, 2023, 12:00 to 1:00 pm CDT, Poster #FRI-545\n\n\n* During this session, this abstract will also be featured as a Rapid Fire oral presentation #RF-11\n\n\nTitle: VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor in Development for Thyroid Eye Disease (TED): Pharmacodynamic Responses in Healthy Volunteers and Patients with Active TED\nSession: Thyroid Biology & Cancer: Thyroid Autoimmunity\nInformation: Friday, June 16, 2023, 12:00 to 1:00 pm CDT, Poster #FRI-546\n\n\nClinical data in these presentations relate exclusively to treatment of patients with active TED. The Company plans to provide an update in J...